XM does not provide services to residents of the United States of America.
N
N

Novartis

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

UBS makes Ermotti Europe's best-paid bank boss with $16 mln package

UPDATE 4-UBS makes Ermotti Europe's best-paid bank boss with $16 mln package Ermotti earned $15.9 mln in 2023, overall bonus pool shrinks UBS says Ermotti could stay beyond Credit Suisse integration More than 1,000 key risk takers earn average of $1.7 mln Adds details on risk takers at UBS in paragraphs 12-16 By Noele Illien ZURICH, March 28 (Reuters) - UBS UBSG.S Chief Executive Sergio Ermotti earned 14.4 million Swiss francs ($15.90 million) in 2023, making him the best paid boss among leading
H
N
S
U

BMW, Life Science REIT, SGL Carbon

EUROPE RESEARCH ROUNDUP-BMW, Life Science REIT, SGL Carbon March 27 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including BMW, Life Science REIT and SGL Carbon on Wednesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Morgan Stanley raises to overweight from equal-weight * BMW BMWG.DE : Jefferies cuts to hold from buy * Credit Agricole SA CAGR.PA : Deutsche Bank raises to buy from hold * Life Science REIT Plc LABS.L : Jefferies cuts to hold from buy
A
B
B
B
B
C
C
C
D
E
E
E
F
H
H
L
N
O
S
A

Obesity drugs inch closer to outsize expectations

RPT-BREAKINGVIEWS-Obesity drugs inch closer to outsize expectations The author is a Reuters Breakingviews columnist. The opinions expressed are their own. NEW YORK, March 22 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO and Eli Lilly LLY.N have inched closer to justifying their enormous valuations. The U.S. government said Thursday it would pay for patients covered by Medicare – the publicly financed health insurance offered to older Americans – to use weight loss drug Wegovy and potential
N

Obesity drugs inch closer to outsize expectations

RPT-BREAKINGVIEWS-Obesity drugs inch closer to outsize expectations The author is a Reuters Breakingviews columnist. The opinions expressed are their own. NEW YORK, March 22 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO and Eli Lilly LLY.N have inched closer to justifying their enormous valuations. The U.S. government said Thursday it would pay for patients covered by Medicare – the publicly financed health insurance offered to older Americans – to use weight loss drug Wegovy and potential
N

Obesity drugs inch closer to outsize expectations

BREAKINGVIEWS-Obesity drugs inch closer to outsize expectations The author is a Reuters Breakingviews columnist. The opinions expressed are their own. NEW YORK, March 22 (Reuters Breakingviews) - Novo Nordisk NOVOb.CO and Eli Lilly LLY.N have inched closer to justifying their enormous valuations. The U.S. government said Thursday it would pay for patients covered by Medicare – the publicly financed health insurance offered to older Americans – to use weight loss drug Wegovy and potentially Z
N

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.